135 related articles for article (PubMed ID: 20430904)
1. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
Del Mastro L; Bighin C; Bini G; Giraudi S; Taveggia P; Levaggi A; Canavese G; Rescinito G; Pronzato P
Ann Oncol; 2010 Jun; 21(6):1376-1377. PubMed ID: 20430904
[No Abstract] [Full Text] [Related]
2. Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?
Bozovic-Spasojevic I; Azim HA; Paesmans M; Suter T; Piccart MJ; de Azambuja E
Lancet Oncol; 2011 Mar; 12(3):209-11. PubMed ID: 21354372
[No Abstract] [Full Text] [Related]
3. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
[TBL] [Abstract][Full Text] [Related]
4. [Trastuzumab administered concurrently with anthracycline-containing adjuvant regimen for breast cancer].
Shen S; Xu Y; Sun Q; Wang C; Zhou Y; Mao F; Guan J; Lin Y; Wang X; Han S
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):132-6. PubMed ID: 24796463
[TBL] [Abstract][Full Text] [Related]
5. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
Liao N; Zhang GC; Li XR; Yao M; Wang K
Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
[TBL] [Abstract][Full Text] [Related]
6. [The requirements to clinicopathology about targeted therapy for breast cancer].
Jiang ZF; Shen G
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
[No Abstract] [Full Text] [Related]
7. Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
Kikuchi Y; Takano M; Kudoh K; Kita T; Sato K
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):189-91. PubMed ID: 18778887
[No Abstract] [Full Text] [Related]
8. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
9. Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer.
Winer EP; Harris JR; Smith BL; D'Alessandro HA; Brachtel EF
N Engl J Med; 2007 Oct; 357(16):1640-8. PubMed ID: 17942877
[No Abstract] [Full Text] [Related]
10. [Primary systemic chemotherapy for breast cancer].
Takada M; Toi M
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1730-4. PubMed ID: 18030005
[TBL] [Abstract][Full Text] [Related]
11. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
12. Can we abandon anthracyclines for early breast cancer patients?
Henderson IC
Oncology (Williston Park); 2011 Feb; 25(2):115-24, 127. PubMed ID: 21456382
[TBL] [Abstract][Full Text] [Related]
13. [A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab].
Nakajima H; Mizuta N; Mizuta M; Nakatsukasa K; Kobayashi A; Hachimine Y; Sakaguchi K; Fujiwara I; Sawai K
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1305-8. PubMed ID: 16969030
[TBL] [Abstract][Full Text] [Related]
14. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F; Yuan P; Zhu W; Wang J; Ma F; Fan Y; Xu B
Med Oncol; 2014 Dec; 31(12):340. PubMed ID: 25416049
[TBL] [Abstract][Full Text] [Related]
15. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
[No Abstract] [Full Text] [Related]
16. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Ahluwalia MS; Daw HA
J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
[No Abstract] [Full Text] [Related]
18. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
19. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
[TBL] [Abstract][Full Text] [Related]
20. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
